Taiwan
· Delayed Price · Currency is TWD BIONET Statistics
Total Valuation
BIONET has a market cap or net worth of TWD 3.56 billion. The enterprise value is 3.14 billion.
| Market Cap | 3.56B |
| Enterprise Value | 3.14B |
Important Dates
The next estimated earnings date is Monday, August 11, 2025.
| Earnings Date | Aug 11, 2025 |
| Ex-Dividend Date | Sep 19, 2024 |
Share Statistics
BIONET has 50.61 million shares outstanding. The number of shares has increased by 0.14% in one year.
| Current Share Class | 50.61M |
| Shares Outstanding | 50.61M |
| Shares Change (YoY) | +0.14% |
| Shares Change (QoQ) | -0.35% |
| Owned by Insiders (%) | 9.44% |
| Owned by Institutions (%) | 0.18% |
| Float | 39.97M |
Valuation Ratios
The trailing PE ratio is 46.55.
| PE Ratio | 46.55 |
| Forward PE | n/a |
| PS Ratio | 2.92 |
| PB Ratio | 1.54 |
| P/TBV Ratio | 2.89 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 32.07 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 38.41, with an EV/FCF ratio of -10,739.72.
| EV / Earnings | 40.97 |
| EV / Sales | 2.58 |
| EV / EBITDA | 38.41 |
| EV / EBIT | 77.06 |
| EV / FCF | -10,739.72 |
Financial Position
The company has a current ratio of 4.43, with a Debt / Equity ratio of 0.04.
| Current Ratio | 4.43 |
| Quick Ratio | 4.15 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | 1.22 |
| Debt / FCF | -342.41 |
| Interest Coverage | 31.37 |
Financial Efficiency
Return on equity (ROE) is 2.42% and return on invested capital (ROIC) is 1.20%.
| Return on Equity (ROE) | 2.42% |
| Return on Assets (ROA) | 0.91% |
| Return on Invested Capital (ROIC) | 1.20% |
| Return on Capital Employed (ROCE) | 1.52% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.43 |
| Inventory Turnover | 6.77 |
Taxes
In the past 12 months, BIONET has paid 30.98 million in taxes.
| Income Tax | 30.98M |
| Effective Tax Rate | 38.57% |
Stock Price Statistics
The stock price has decreased by -28.00% in the last 52 weeks. The beta is 0.50, so BIONET's price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | -28.00% |
| 50-Day Moving Average | 71.12 |
| 200-Day Moving Average | 83.97 |
| Relative Strength Index (RSI) | 50.26 |
| Average Volume (20 Days) | 124,725 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BIONET had revenue of TWD 1.22 billion and earned 76.54 million in profits. Earnings per share was 1.51.
| Revenue | 1.22B |
| Gross Profit | 681.18M |
| Operating Income | 40.69M |
| Pretax Income | 80.31M |
| Net Income | 76.54M |
| EBITDA | 70.10M |
| EBIT | 40.69M |
| Earnings Per Share (EPS) | 1.51 |
Balance Sheet
The company has 1.57 billion in cash and 99.98 million in debt, giving a net cash position of 1.47 billion or 29.14 per share.
| Cash & Cash Equivalents | 1.57B |
| Total Debt | 99.98M |
| Net Cash | 1.47B |
| Net Cash Per Share | 29.14 |
| Equity (Book Value) | 2.31B |
| Book Value Per Share | 24.85 |
| Working Capital | 1.56B |
Cash Flow
In the last 12 months, operating cash flow was 110.93 million and capital expenditures -111.22 million, giving a free cash flow of -292,000.
| Operating Cash Flow | 110.93M |
| Capital Expenditures | -111.22M |
| Free Cash Flow | -292,000 |
| FCF Per Share | -0.01 |
Margins
Gross margin is 56.00%, with operating and profit margins of 3.35% and 6.29%.
| Gross Margin | 56.00% |
| Operating Margin | 3.35% |
| Pretax Margin | 6.60% |
| Profit Margin | 6.29% |
| EBITDA Margin | 5.76% |
| EBIT Margin | 3.35% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 1.41, which amounts to a dividend yield of 2.09%.
| Dividend Per Share | 1.41 |
| Dividend Yield | 2.09% |
| Dividend Growth (YoY) | 9.05% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 43.31% |
| Buyback Yield | -0.14% |
| Shareholder Yield | 1.86% |
| Earnings Yield | 2.15% |
| FCF Yield | -0.01% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 19, 2024. It was a forward split with a ratio of 1.070923771.
| Last Split Date | Sep 19, 2024 |
| Split Type | Forward |
| Split Ratio | 1.070923771 |
Scores
BIONET has an Altman Z-Score of 4.33 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.33 |
| Piotroski F-Score | 5 |